Pharmaceutical News

RSS

NSAIDs protect against colorectal cancer by inducing cell suicide pathways in intestinal stem cells

Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) protect against the development of colorectal cancer by inducing cell suicide pathways in intestinal stem cells that carry a certain mutated and dysfunctional gene, according to a new study led by researchers at the University of Pittsburgh Cancer Institute and the School of Medicine.

4 Nov 2014

Anesthetics can cause long-term memory loss, reveal University of Toronto researchers

Researchers at the University of Toronto's Faculty of Medicine have shown why anesthetics can cause long-term memory loss, a discovery that can have serious implications for post-operative patients.

4 Nov 2014

Nasal vaccine shows promise against Ebola virus

A nasal vaccine in development by researchers at The University of Texas at Austin has been shown to provide long-term protection for non-human primates against the deadly Ebola virus. Results from a small pre-clinical study represent the only proof to date that a single dose of a non-injectable vaccine platform for Ebola is long-lasting, which could have significant global implications in controlling future outbreaks.

4 Nov 2014

FDA approves Fluzone High-Dose vaccine sBLA to include efficacy data in Prescribing Information

Sanofi Pasteur, the vaccines division of Sanofi, today announced that the U.S. Food and Drug Administration has approved the supplemental biologics license application (sBLA) for Fluzone High-Dose (Influenza Vaccine) to include efficacy data in the Prescribing Information.

3 Nov 2014

Astellas' isavuconazole gets FDA orphan drug designation for treatment of invasive candidiasis

Astellas announced today that the U.S. Food and Drug Administration has granted orphan drug designation to isavuconazole for the treatment of invasive candidiasis.

3 Nov 2014

Epicure project: an interview with Frédéric Cren

Epicure is a project led by Inventiva and Institut Curie that aims to deliver pre-clinical candidates on two novel epigenetic targets that have been selected due to their potential to activate immune responses against cancer cells. In addition one of these two targets has potential in respiratory indications such as asthma or COPD.

3 Nov 2014

Gates Foundation awards US$156 million to support PATH Malaria Vaccine Initiative

In support of a bold quest to rid the world entirely of malaria, the Bill & Melinda Gates Foundation today announced an award of US$156 million to PATH to support the PATH Malaria Vaccine Initiative (MVI) in building new vaccines that will interrupt the cycle of malaria parasite transmission and help realize the "accelerating to zero" agenda. Such vaccines would ensure that parasite reintroduction is prevented by providing what could be called an "immunological bed net."

3 Nov 2014

Diabetes treatment with low-cost generic drug can have positive implications for patient's quality of life

New research from CVS Health finds starting a new diabetes patient on metformin, a generic oral diabetes medicine that helps control blood sugar levels, reduced the need to add on additional treatments to control the condition over time. Although there are many classes of oral diabetes medications, there has historically been little evidence available on the comparative effectiveness of treatments to help patients and providers select an initial diabetes therapy.

31 Oct 2014

Profectus BioSciences gets funding to develop VesiculoVax Zaire-Ebola virus vaccine

Profectus BioSciences, Inc., a clinical-stage vaccine company developing novel vaccines for the treatment and prevention of infectious diseases, announced today that the Department of Defense through the Medical Countermeasure Systems-Joint Vaccine Acquisition Program, a subordinate command of the Joint Program Executive Office for Chemical and Biological Defense, Edgewood, MD, has contracted the manufacture and IND-enabling preclinical testing of the Profectus trivalent Ebola/Marburg vaccine.

31 Oct 2014

New consensus guidelines for toxicity testing of oligonucleotide-based therapeutics

Oligonucleotide-based therapeutics present unique challenges when it comes to testing their potential to cause reproductive and developmental harm. New consensus guidelines for toxicity testing that take into consideration the combined chemical and biological characteristics of these novel biopharmaceuticals are presented in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers.

31 Oct 2014

Veloxis receives tentative FDA approval for Envarsus XR

Veloxis Pharmaceuticals A/S announced today that the U.S. Food and Drug Administration has informed Veloxis of the tentative approval of Envarsus XR. FDA stated that the final approval of Envarsus XR will be delayed until expiration of the exclusivity period for Astellas' Astagraf XL.

31 Oct 2014

Dosing of antiretroviral medication to prevent HIV infection differs by sex

A mathematical model developed by NIH grantees predicts that women must take the antiretroviral medication Truvada daily to prevent HIV infection via vaginal sex, whereas just two doses per week can protect men from HIV infection via anal sex.

31 Oct 2014

New therapy appears to help tinnitus patients cope better with phantom noise

Patients with tinnitus hear phantom noise and are sometimes so bothered by the perceived ringing in their ears, they have difficulty concentrating. A new therapy does not lessen perception of the noise but appears to help patients cope better with it in their daily lives, according to new research.

31 Oct 2014

Migranade makes available new migraine medication for U.S. migraine sufferers

Migranade, Inc. announced today the new migraine medication, MIGRANADE Migraine Relief will be available to the 36 million U.S. migraine sufferers November, 2014.

30 Oct 2014

FDA recommens approval of Daiichi Sankyo's once-daily SAVAYSA for patients with NVAF

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the U.S. Food and Drug Administration's Cardiovascular and Renal Drugs Advisory Committee voted 9 to 1 to recommend approval of once-daily SAVAYSA (edoxaban) 60 mg dosing regimen for the reduction in risk of stroke and systemic embolic events (SEE) in patients with non-valvular atrial fibrillation (NVAF).

30 Oct 2014

Neurocrine Biosciences' NBI-98854 drug gets breakthrough designation for tardive dyskinesia

Neurocrine Biosciences, Inc. announced today that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation for its Vesicular Monoamine Transporter 2 inhibitor, NBI-98854, in tardive dyskinesia.

30 Oct 2014

International Aspirin Foundation introduces two biennial awards

In celebration of the 40th anniversary of the formation of The International Aspirin Foundation, we are delighted to announce the introduction of two biennial awards; a Senior Science Award and a Young Investigator Award.

30 Oct 2014

NCI supports further clinical development of next-generation HPV vaccine

The National Cancer Institute in the USA is supporting the new vaccine developed at the MedUni Vienna against the human papillomavirus (HPV) with at least US$ 3.5 million. This is a major success for the developers and means that the foundations can now be laid for the clinical trials needed for licensing as a vaccine.

30 Oct 2014

Kiadis Pharma's ATIR product receives EMA's ODD for treatment of acute myeloid leukemia

Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing T-cell immunotherapy treatments for blood cancers, today announces that its lead product ATIR has been granted Orphan Drug Designation (ODD) by the European Medicines Agency for the treatment of acute myeloid leukemia (AML).

30 Oct 2014

Drug-loaded plaster delivers active agent to premature babies via membrane

The development of minimally and even non-invasive technologies is increasing in the medical field. It is now possible, for instance, to carry out a range of operative procedures using keyhole surgery with minimal use of the scalpel, leaving only tiny scars as a result. Similar opportunities are now becoming available when providing doses of active agents to patients – instead of using injections or probes to deliver drugs, it will in future be possible to supply them via a plaster which continuously, gently and painlessly delivers the required dosage through the skin.

30 Oct 2014

Pharmaceutical News

NSAIDs protect against colorectal cancer by inducing cell suicide pathways in intestinal stem cells

Anesthetics can cause long-term memory loss, reveal University of Toronto researchers

Nasal vaccine shows promise against Ebola virus

FDA approves Fluzone High-Dose vaccine sBLA to include efficacy data in Prescribing Information

Astellas' isavuconazole gets FDA orphan drug designation for treatment of invasive candidiasis

Epicure project: an interview with Frédéric Cren

Gates Foundation awards US$156 million to support PATH Malaria Vaccine Initiative

Diabetes treatment with low-cost generic drug can have positive implications for patient's quality of life

Profectus BioSciences gets funding to develop VesiculoVax Zaire-Ebola virus vaccine

New consensus guidelines for toxicity testing of oligonucleotide-based therapeutics

Veloxis receives tentative FDA approval for Envarsus XR

Dosing of antiretroviral medication to prevent HIV infection differs by sex

New therapy appears to help tinnitus patients cope better with phantom noise

Migranade makes available new migraine medication for U.S. migraine sufferers

FDA recommens approval of Daiichi Sankyo's once-daily SAVAYSA for patients with NVAF

Neurocrine Biosciences' NBI-98854 drug gets breakthrough designation for tardive dyskinesia

International Aspirin Foundation introduces two biennial awards

NCI supports further clinical development of next-generation HPV vaccine

Kiadis Pharma's ATIR product receives EMA's ODD for treatment of acute myeloid leukemia

Drug-loaded plaster delivers active agent to premature babies via membrane

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Latest News